Small molecule · developed by Traws Pharma
ON 01910.Na is an intravenously administered agent studied in myelodysplastic syndrome, given as 5-day continuous infusions every two weeks.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00867061 | Phase 1/2 | Myelodysplastic Syndrome | Withdrawn | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myelodysplastic Syndrome
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →